Growth Hormone in IVF: What the Evidence Shows and Why It Remains Controversial

What growth hormone is and why it is considered in IVF

Growth hormone (GH), also known as somatotropin, is a pituitary hormone that plays roles in cell growth, metabolism, and tissue repair throughout the body. In the context of IVF, GH has been investigated as a supplementary medication for patients whose ovaries respond poorly to standard gonadotropin stimulation.

The rationale is that GH and its downstream mediator IGF-1 may enhance follicle development, improve oocyte quality, and promote endometrial receptivity. These mechanisms have been demonstrated in laboratory and animal studies, but translating laboratory findings into clinical benefit in human IVF has proven difficult.

GH is not a first-line IVF medication. It is considered an add-on, typically offered to patients who have had one or more cycles with poor response or repeated failure despite appropriate stimulation doses.

What the evidence says for poor responders

Several meta-analyses have examined GH supplementation in poor ovarian responders. The overall signal is that GH may increase the number of oocytes retrieved and possibly improve clinical pregnancy rates, but the effect on live birth rates is less clear. The studies included in these analyses vary in quality, patient population, GH dose, and timing of administration, which makes definitive conclusions difficult.

A Cochrane review noted that the quality of evidence is low to very low for most outcomes, meaning that the true effect could be substantially different from what the available studies suggest. The review called for larger, well-designed trials before GH can be recommended as standard practice.

Some individual randomized trials have shown positive results, particularly the LIGHT trial, which reported improved live birth rates in poor responders who received GH. However, this trial has been debated for its design and the generalizability of its findings. Other trials have shown no benefit.

What the evidence says for other indications

Recurrent implantation failure. Some clinicians use GH for patients who have had multiple failed transfers with euploid embryos. The hypothesis is that GH improves endometrial receptivity, possibly through increased endometrial thickness, blood flow, or immune modulation. The evidence for this indication is even weaker than for poor response, consisting primarily of small observational studies and case series.

Thin endometrium. GH has been tried for patients with persistently thin endometrial lining that does not respond to standard estrogen supplementation. Again, the evidence is limited to small studies with mixed results.

Advanced maternal age. Some clinics offer GH to patients over 38 or 40 regardless of ovarian reserve markers, on the theory that it may improve egg quality. This is speculative and not supported by consistent evidence.

Why the controversy persists

The IVF add-on landscape is crowded with interventions that have plausible biological rationale but insufficient clinical evidence. GH sits in this category. The challenge is that conducting large enough trials to detect a meaningful difference in live birth rates is expensive and logistically difficult, especially in a population, poor responders, that is inherently heterogeneous.

Clinics that offer GH may genuinely believe in its potential based on their own experience and the subset of studies that show positive results. Clinics that do not offer it may point to the same literature and conclude that the evidence does not justify the cost. Both positions can be defended, which is why the debate continues.

For patients, the key question is not whether GH works in theory but whether it is worth the cost in their specific situation, given the uncertainty. A clinic that recommends GH should be able to explain which studies support their recommendation, acknowledge the limitations of those studies, and present the cost transparently.

Cost considerations

Growth hormone is one of the more expensive add-ons in IVF. The cost depends on the dose, which varies by protocol, and the duration of use, which can range from a few days during stimulation to several weeks of pre-treatment. In the US, a cycle of GH may add 800 to 2,000 dollars. In countries with different pharmaceutical pricing structures, the cost may be substantially lower.

For patients already facing the high cost of IVF, an additional expense with uncertain benefit requires careful consideration. If the patient has limited financial resources and must choose between GH and another cycle, the additional cycle may provide more predictable value. If the patient has already had multiple failed cycles and is looking for any intervention that might change the outcome, the calculus may be different.

Insurance almost never covers GH for IVF. It is paid entirely out of pocket in most settings.

How to make the decision

Ask the clinic three questions. First, what specific evidence supports using GH for my situation? Second, what is the expected benefit in terms of eggs, embryos, or pregnancy probability? Third, what is the total cost including the medication, additional monitoring, and any administration fees?

If the clinic presents GH as a guaranteed improvement, that is a yellow flag. If they present it as an option with potential benefit and acknowledged uncertainty, that is more credible. If they recommend it for every patient regardless of diagnosis, the recommendation may be commercially rather than clinically motivated.

Patients who decide to use GH should do so with clear expectations: it might help, it might not, and the evidence will not give a definitive answer either way. That is an uncomfortable position, but it is an honest one.

Evidence changes. Ask your clinician what has changed since you last reviewed your plan.

Related: IVF Add-Ons: Which Are Evidence-Based?